Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Mar;10(3):241-52.
doi: 10.1016/S1474-4422(10)70325-2.

Apolipoprotein E in Alzheimer's disease and other neurological disorders

Philip B Verghese  1 , Joseph M Castellano, David M Holtzman
Affiliations
Review

Apolipoprotein E in Alzheimer's disease and other neurological disorders

Philip B Verghese et al. Lancet Neurol. 2011 Mar.

Abstract

Apolipoprotein E (APOE) is a 299-aminoacid protein encoded by the APOE gene. Three common polymorphisms in the APOE gene, ɛ2, ɛ3, and ɛ4, result in a single aminoacid change in the APOE protein. APOE ɛ2, ɛ3, and ɛ4 alleles strongly alter, in a dose-dependent manner, the likelihood of developing Alzheimer's disease and cerebral amyloid angiopathy. In particular, APOE ɛ4 is associated with increased risk for Alzheimer's disease whereas APOE ɛ2 is associated with decreased risk. The effects of APOE genotype on risk of these diseases are likely to be mediated by differential effects of APOE on amyloid-β accumulation in the brain and its vasculature. Response to treatment for Alzheimer's disease might differ according to APOE genotype. Because convincing evidence ties the APOE genotype to risk of Alzheimer's disease and cerebral amyloid angiopathy, APOE has been studied in other neurological diseases. APOE ɛ4 is associated with poor outcome after traumatic brain injury and brain haemorrhage, although the mechanisms underlying these associations are unclear. The possibility that APOE has a role in these and other neurological diseases has been of great interest, but convincing associations have not yet emerged.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: The authors PBV and JMC have no conflicts of interests. DMH receives payment for being on the scientific advisory boards of En Vivo and Satori. He has also received payments from C2N Diagnostics, LLC as a scientific advisor as well as royalties from a Washington University patent licensed to C2N. Washington University receives grants from Eli-Lilly and Pfizer that supports research in the laboratory of DMH.

Figures

Figure 1
Figure 1
A large body of evidence suggests that the dominant effect of human apoE isoforms on AD risk is to shift the onset of disease via alterations in the probability of amyloid deposition, likely during the preclinical, asymptomatic phase. Consistent with this hypothesis, individuals appear to accumulate amyloid in the order ε4 > ε3 > ε2, well before AD clinical symptomology becomes manifest (Figure adapted from Holtzman, DM 2008 Nature, 454(7203):418–20).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science. 1993;261:921–3. - PubMed
    1. Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer’s disease. Neurology. 1993;43:1467–72. - PubMed
    1. Saunders AM. Apolipoprotein E and Alzheimer disease: an update on genetic and functional analyses. J Neuropathol Exp Neurol. 2000;59:751–8. - PubMed
    1. Roses AD. Apolipoprotein E alleles as risk factors in Alzheimer’s disease. Annu Rev Med. 1996;47:387–400. - PubMed
    1. Poirier J, Davignon J, Bouthillier D, Kogan S, Bertrand P, Gauthier S. Apolipoprotein E polymorphism and Alzheimer’s disease. Lancet. 1993;342:697–9. - PubMed

Publication types

MeSH terms

Substances